Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Galera Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Galera Therapeutics, Inc.

GRTX

Galera Therapeutics, Inc.

About Galera Therapeutics, Inc.

Galera Therapeutics is a biopharmaceutical company focused on developing small molecule therapies to mitigate side effects of cancer radiotherapy, such as oral mucositis. Its portfolio includes SOD mimetics and a pan-NOS inhibitor targeting aggressive breast cancers like triple-negative and metaplastic subtypes. The company advances clinical-stage candidates, collaborates with research institutions, and relies on third-party manufacturing, aiming to improve cancer treatment outcomes through innovative, targeted therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Galera Therapeutics, Inc.

1
1
Galera Therapeutics, Inc. Galera Therapeutics Reports Q1 2026 Financial Results, Faces Going Concern Risks

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Galera Therapeutics, Inc. Galera Therapeutics Reports $149M Net Income Turnaround in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Galera Therapeutics, Inc. Galera Therapeutics Reports Improved Financial Results with $1.4 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Galera Therapeutics, Inc. Galera Therapeutics Reports $2.7 Million Net Loss, Workforce Reduction and Strategic Acquisition

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Galera Therapeutics, Inc. Galera Therapeutics Reports $1.6 Million Net Loss in Q1 2025, Focuses on New Cancer Treatment

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Galera Therapeutics, Inc. Galera Therapeutics Reports Decline in Financial Performance and Strategic Acquisition of Nova Pharmaceuticals

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Galera Therapeutics, Inc. Galera Therapeutics Reports $5.6M Net Loss, Faces Financial Challenges and Workforce Reduction

Via official filing (AI summary) | over 1 year ago | 0 comments